Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Blood (2011) 118 (21): 3976.

https://doi.org/10.1182/blood.V118.21.3976.3976

Published: 2011

Journal Articles

Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,

Veroniki Komninaka, Theodore Marinakis, Dimitrios Christoulas, Konstantina Repa, Dionysia Kolomodi, Maria Mitropoulou, Maria Gkotzamanidou, Athanasios Papatheodorou, Nikolaos Anagnostopoulos, Meletios Athanasios Dimopoulos, MD, Evangelos Terpos

Blood (2011) 118 (21): 3215.

https://doi.org/10.1182/blood.V118.21.3215.3215

Published: 2011

Journal Articles

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,

Meletios Athanasios Dimopoulos, MD, Antonio Palumbo, MD, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, MD, Philip Lewis, PhD, Stefanie Millar, Jingshan Zhang, PhD, Jay Mei, MD, PhD, Michel Delforge, MD, PhD

Blood (2011) 118 (21): 3988.

https://doi.org/10.1182/blood.V118.21.3988.3988

Published: 2011

Journal Articles

Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma,

Evangelos Terpos, Gerasimos-Petros Papassotiriou, Efstathios Kastritis, Maria Gkotzamanidou, Dimitrios Christoulas, Evangelos Eleutherakis-Papaiakovou, Alexandra Margeli, Magdalini Migkou, Maria Gavriatopoulou, Maria Roussou, Ioannis Papassotiriou, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3918.

https://doi.org/10.1182/blood.V118.21.3918.3918

Published: 2011

Journal Articles

Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,

Lia A Moulopoulos, Efstathios Kastritis, Evangelos Terpos, Maria Gkotzamanidou, Maria Roussou, Andreas Koureas, Magdalini Migkou, Maria Gavriatopoulou, Dimitra Gika, Vasilios Koutoulidis, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3920.

https://doi.org/10.1182/blood.V118.21.3920.3920

Published: 2011

Journal Articles

Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,

Evangelos Terpos, Dimitrios Christoulas, Maria Gkotzamanidou, Evangelos Eleutherakis-Papaiakovou, Athanasios Papatheodorou, Anastasia Pouli, Efstathios Kastritis, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3922.

https://doi.org/10.1182/blood.V118.21.3922.3922

Published: 2011

Journal Articles

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,

Efstathios Kastritis, Lia A Moulopoulos, Maria Gkotzamanidou, Dimitra Gika, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3926.

https://doi.org/10.1182/blood.V118.21.3926.3926

Published: 2011

Journal Articles

Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients

Evangelos Terpos, Efstathios Kastritis, Despoina Iakovaki, Maria Gkotzamanidou, Magdalini Migkou, Georgia Bardi, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 1811.

https://doi.org/10.1182/blood.V118.21.1811.1811

Published: 2011

Journal Articles

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Meletios Athanasios Dimopoulos, MD, Meral Beksac, MD, Lotfi Benboubker, MD, PhD, Huw Roddie, MBChB, PhD, Nathalie Allietta, Esther Broer, Catherine Couturier, PharmD, Marie-Andrée Mazier, DESS, Ralf Angermund, MD, Thierry Facon, MD

Blood (2011) 118 (21): 1861.

https://doi.org/10.1182/blood.V118.21.1861.1861

Published: 2011

Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

Blood (2011) 118 (21): 475.

https://doi.org/10.1182/blood.V118.21.475.475

Published: 2011

Journal Articles

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

David S. Siegel, MD, PhD, Meletios Athanasios Dimopoulos, MD, Sung-Soo Yoon, MD, PhD, Jacob P. Laubach, MD, Jonathan L. Kaufman, MD, Hartmut Goldschmidt, MD, Donna E. Reece, MD, FRCPC, Xavier Leleu, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Fritz C. Offner, MD, PhD, Michele Cavo, MD, Arnon Nagler, MD, Sundar Jagannath, MD, Thorsten Graef, MD, PhD, Jennifer Houp, Linda Sun, PhD, Jason Howe, Sandra M. Wear, RN, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 480.

https://doi.org/10.1182/blood.V118.21.480.480

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome

Evangelos Terpos, Bouchra Asli, MD, Dimitrios Christoulas, Jean-Claude Brouet, Efstathios Kastritis, Michel Rybojad, Meletios Athanasios Dimopoulos, MD, Jean Paul Fermand, MD

Blood (2011) 118 (21): 1802.

https://doi.org/10.1182/blood.V118.21.1802.1802

Published: 2011

Journal Articles

High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Peggy Lymberi, Evangelos Terpos, Aikaterini Hatzioannou, Evangelos Eleutherakis-Papaiakovou, Apostolos Balafas, Efstathios Kastritis, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 2893.

https://doi.org/10.1182/blood.V118.21.2893.2893

Published: 2011

Journal Articles

Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival

Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Anna Tasidou, Dimitrios Christoulas, Maria Gavriatopoulou, Maria Gkotzamanidou, Maria Roussou, Theodora Papadaki, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 2894.

https://doi.org/10.1182/blood.V118.21.2894.2894

Published: 2011

Journal Articles

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression

Meletios Athanasios Dimopoulos, MD, Michel Delforge, MD, PhD, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, MD, Philip Lewis, PhD, Stefanie Millar, Jingshan Zhang, PhD, Jay Mei, MD, PhD, Antonio Palumbo, MD

Blood (2011) 118 (21): 3157.

https://doi.org/10.1182/blood.V118.21.3157.3157

Published: 2011

Journal Articles

Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma

Maria Gkotzamanidou, Evangelos Terpos, Petros P. Sfikakis, Meletios Athanasios Dimopoulos, MD, Vassilis L. Souliotis

Blood (2011) 118 (21): 299.

https://doi.org/10.1182/blood.V118.21.299.299

Published: 2011

Journal Articles

Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations

Tina Bagratuni, Efstathios Kastritis, Maria Roussou, Dimitrios Christoulas, Efthimios Kostouros, Marianna Politou, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 2872.

https://doi.org/10.1182/blood.V118.21.2872.2872

Published: 2011

Journal Articles

Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Meletios Athanasios Dimopoulos, MD, Mohamad Hussein, MD, Arlene S Swern, PhD, Donna M. Weber, MD

Blood (2011) 118 (21): 2929.

https://doi.org/10.1182/blood.V118.21.2929.2929

Published: 2011

Journal Articles

Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?

Evangelos Terpos, Meletios Athanasios Dimopoulos, MD, Stephanie Harel, MD, Francis K Buadi, M.D., Dimitrios Christoulas, Ersi Voskaridou, Efstathios Kastritis, Jean Paul Fermand, MD, Angela Dispenzieri, MD

Blood (2011) 118 (21): 806.

https://doi.org/10.1182/blood.V118.21.806.806

Published: 2011

NARROW

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,

Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma,

Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,

Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,

Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome

High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression

Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma

Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations

Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only